Prader-Willi syndrome—different patients, different attitude

Anamaria Bursuc1, Alina Belceanu1, Ioana Armasu1, Georgiana Constantinescu1, Daniela Boisteana2, Cristina Rusu3, Letitia Leustean1, Carmen Vulpoi1
1 – Department of Endocrinology, 2 – Department of Pneumology, 3 - Department of Genetics
University of Medicine and Pharmacy “Grigore T. Popa” – Iași, Romania

Introduction

- Prader-Willi Syndrome (PWS) is a multisystemic genetic disorder caused by lack of expression of genes on the paternally inherited chromosome 15q11.2-q13 characterized by:
  - dysmorphic features, hypotonia, mental retardation, behavioral abnormalities, hyperphagia with progressive obesity and endocrine dysfunctions as hypogonadism and GH deficiency (GHD) (1)
  - Risk factors for mortality in PWS include severe obesity, obstructive sleep apnea, upper respiratory tract infections (URI), aspiration, and tonsil/adenoid hypertrophy
  - The major cause of morbidity and mortality is severe obesity
  - which can be controlled externally by diet restrictions and behavior modification (2)
- Early diagnosis is important:
  - to effective long-term management
  - prevent complications
  - prolong life expectancy
- Growth hormone treatment improves growth, physical phenotype and body composition (3)

Case reports

Case 1. – Diana, 21 years

- Facies: Acromicria
- 1st years of life:
  - Important hypotonia
  - Failure to thrive in the first 6 months
  - Mental and motor retardation
  - Hypophagia started at 4th year of life
  - General seizures by the age of 2
  - Sleep apnea
- 18 years old:
  - Obesity: 84.3 kg, BMI = 34.6 kg/m2
  - Final height: 158 cm (-0.5 SD)
  - Fat mass: (electrical impedance) 34%
- Clinical examination:
  - Narrow forehead
  - discrete almond-shaped palpebral fissures
  - acromicria
  - Genital development: telearche (B3-4)
  - Menarche absent
  - Important mental retardation
- Genetics:
  - 8 years: caryotype 46, XX. Test FISH: del (15)(q11.2-q13)
- Biological tests:
  - Normal thyroid and adrenal axes
  - Normal estradiol and gonadotrophines
  - IGF1: normal (138 mg/dl)
  - At 6 y, low GH (0.2 u/ml), insufficient cholinergic stimulation (5.4 u/g/l)

Case 2. – Fabiana, 11 years

- 1st years of life:
  - Generalized hypotonia
  - Mental and motor retardation
  - Hypophagia started after 1st year of life
- 11 years old:
  - Obesity: 52 kg, BMI for children = 27.3 kg/m2
  - Height: 137.5 cm, -1.2 SD
  - Puberty stage: 3B FII
  - Bone age: 11 years
- Clinical examination:
  - Discrete almond-shaped palpebral fissures
  - Acromicria
  - Acanthus nigricans
  - Dental malposition
  - Moderate mental retardation
- Genetics:
  - At 4 years: caryotype 46, XX; MS-PCR metilization 15q21.1-q23
- Biological tests:
  - Mild hypothyroidism compensate with I13
  - Normal adrenal function
  - Low IGF1 = 66.5 mg/dl (N: 111-155)
  - Low basal GH = 0.05 mg/ml, without stimulation at the arginine test

Case 3. – Vlad, 27 years

- 1st years of life:
  - Generalized hypotonia
  - Psychological and mental retardation
  - Hypophagia started after the 4th year of life
- 17 years old:
  - Obesity: 80 kg
  - Final height: 159 cm, -4.7 SD
  - Epiphysial closure
- Clinical examination:
  - Discrete almond-shaped palpebral fissures
  - Acromicria
  - Acanthus nigricans
  - Severe sleep apnea
  - Moderate mental retardation
- Genetics:
  - Caryotype: 46, XX; del (15)(q11.2-q13)
- Biological tests:
  - Normal thyroid and adrenal axes
  - Low IGF1 = 24.3 mg/ml (N: 350-600)

Case 2

- Achatonis nigricans
- Acromicria

All pictures are reproduced with informed consent.

Discussions

- Our 3 cases presented specific clinical features of PWS and genetic confirmation, but the therapeutic attitude was different for each case:
  - Case 1: 
    - At the age of 10, had important obesity (+10SD) and a surprising height at +2SD despite of partial GHD
    - Her actual height remains higher than expected (-0.5 SD)
    - Although basal GH remains low and IGF1 at the inferior limit, the association of confirmed sleep apnea temporized the GH treatment
  - Case 2:
    - At the age of 11, presented moderate obesity and a height of 137.5 cm (-1.2 SD)
    - The confirmed GHD, with the possible aggravation of obesity, in the absence of sleep apnea, justified the mGH therapy
  - Case 3:
    - Had the first endocrinological examination at the age of 17 years and presented epiphysial closure, with a final height of 159 cm(-2.7SD) and moderate overweight
    - In spite of confirmed GHD, no treatment was initiated because of parents’ option

Conclusions

- With rigorous alimentation and constant psychological and parental support, the weight in our cases did not excessively increase.
- The benefits of GH treatment are substantial as it not only improves physical characteristics and psychomotor development, but also has psychological and behavioral benefits, the major concern being aggravation of sleep apnea (4)
- Aggravation of pre-existing conditions due to GH therapy have been found in some individuals in literature and should be closely monitored.
- GH treatment is recommended and should be individualized for patients with PWS in conjunction with dietary, environmental and lifestyle interventions.

References:
(3) Alan Y Ho and Anastasia Dimitropoulou. Clinical management of behavioral characteristics of Prader Willi syndrome. Neuropsychiatric Disease and Treatment 2010; 6: 107-119